Holen Sie sich die Stockscreener-App
46.35
3.78%
1.69
Vorhandelsmarkt:
46.15
-0.20
-0.43%
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Avidity Biosciences Inc. Charts Flash Early Recovery SignalsEarnings Overview Summary & Fast Gain Swing Trade Alerts - newsimpact.co.kr
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
Technical analysis overview for Avidity Biosciences Inc. stockWeekly Trading Summary & Verified Momentum Watchlists - Newser
Momentum Indicator Shows Bearish Divergence in Avidity Biosciences Inc.July 2025 Technicals & Low Drawdown Momentum Trade Ideas - metal.it
Avidity Biosciences Q2 Earnings: Strong Progress and Financial Position - AInvest
Price Floor Holding on Avidity Biosciences Inc. — Rebound PossibleWeekly Stock Analysis & Weekly Sector Rotation Insights - metal.it
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
What makes Avidity Biosciences Inc. stock price move sharplyJuly 2025 Weekly Recap & Accurate Entry/Exit Alerts - thegnnews.com
Avidity Biosciences Advances RNA Therapeutics with Strong Q2 - TipRanks
Avidity Biosciences (RNA) CHRO McCarthy sells $465k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences (RNA) CHRO McCarthy sells $465k in stock - Investing.com
Avidity Biosciences Executives Sell Shares Under Trading Plans - TradingView
Avidity Biosciences Executives Make Substantial Share Trades Amid Company News - AInvest
Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market - Investing.com
Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market By Investing.com - Investing.com South Africa
Avidity Biosciences Inc. Moves Into Overbought Range Analysts CautiousTrend Analysis for Safer Trades Gains Popularity - 선데이타임즈
Avidity Biosciences RNA 2025Q2 Earnings Preview Upside Potential on Novartis Acquisition Talks - AInvest
Avidity Biosciences' Promising Pipeline: Buy Rating Maintained by Ananda Ghosh - AInvest
Avidity Biosciences Bets Big On Rare Disease Therapies - Finimize
Avidity Biosciences Q2 Results: Analysts Boost Revenue Forecasts, Raise Loss Per Share Estimates - AInvest
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
Avidity (RNA) Gets 26% Jump on Potential Takeover - MSN
Avidity Biosciences price target raised to $75 from $70 at Wells Fargo - MSN
Chardan Capital Maintains "Buy" Rating for Avidity Biosciences with $75 Price Target - AInvest
Insider Selling at Avidity Biosciences: A Signal of Routine Tax Obligations or a Cause for Concern? - AInvest
Avidity Biosciences Insider Selling: Signal or Noise in a High-Potential Biotech Play? - AInvest
Avidity Biosciences Shares Slide 2.59% as 230M-Dollar Volume Ranks 431st Amid Analyst Optimism and Deepening Losses - AInvest
Avidity Biosciences Signs Manufacturing Agreement with Lonza - The Globe and Mail
Avidity Biosciences Insider Trading: Officers Buy and Sell Shares on 2025-08-06 - AInvest
Novartis weighs deal for biotech Avidity Biosciences, FT reports - AOL.com
Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position - TipRanks
Avidity Biosciences: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $75 - AInvest
Avidity Biosciences: Barclays Keeps Overweight Rating, Raises PT to $62 - AInvest
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $75 - 富途牛牛
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $62 - 富途牛牛
Avidity Biosciences: Chardan Capital Maintains Buy, Raises PT to $75 - AInvest
Avidity Biosciences 2025 Q2 Earnings Significant Loss Widening Despite Revenue Surge - AInvest
Avidity (RNA) Q2 Revenue Jumps 88% - AOL.com
Avidity Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avidity Biosciences Reports Q2 2025 Financial Results and Key Milestones, with Strong Cash Position and Upcoming FDA Submissions - AInvest
Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest - AInvest
Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c) - TipRanks
Earnings Flash (RNA) Avidity Biosciences, Inc. Reports Q2 Revenue $3.8M - MarketScreener
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights - Nasdaq
Novartis eyes Avidity Biosciences in potential takeover: Report - Medical Dialogues
Rumour mill says Novartis may want to buy Avidity - pharmaphorum
Avidity Biosciences, Inc. Enters into A Manufacturing Services Agreement with Lonza Ltd and Lonza Sales Ltd - MarketScreener
Novartis's Strategic Pursuit of Avidity Biosciences: A Catalyst for Biotech Value and Long-Term Growth? - AInvest
Avidity Biosciences Surges 26% on 877% Volume Spike to 121st Most Traded as High-Volume Stocks Outperform with 166% Returns - AInvest
Novartis Eyes Avidity Biosciences Acquisition to Boost Rare Disease Pipeline - AInvest
Avidity Shares Surge 20% Following Report of Buyout Interest - AInvest
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):